Peer-reviewed veterinary case report
Survival factors in dogs with adrenal hyperadrenocorticism
By Helm, J R et al.·Published in Journal of veterinary internal medicine·2011·School of Veterinary Medicine, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane.
- Species:
- dog
Plain-English summary
A group of dogs with adrenal-dependent hyperadrenocorticism (ADH), a condition that causes excessive hormone production, were treated with either mitotane or trilostane to see which treatment helped them live longer. The study found that the survival times for dogs treated with trilostane averaged about 353 days, while those on mitotane lived around 102 days. However, the type of medication didn't significantly affect survival; rather, dogs with metastatic disease (cancer that has spread) had a much lower chance of survival, regardless of the treatment used.
People also search for: dog adrenal disease treatment · mitotane vs trilostane for dogs · dog cancer survival rates
Abstract
BACKGROUND: Trilostane is a recognized treatment for canine pituitary-dependent hyperadrenocorticism (PDH); however, its efficacy in dogs with adrenal-dependent hyperadrenocorticism (ADH) is unknown. OBJECTIVES: To examine factors that might influence survival in the medical management of ADH, with particular emphasis on treatment selection. ANIMALS: Thirty-seven animals referred to 4 centers over a period of 12 years that had been diagnosed with ADH and treated with either trilostane (22/37), mitotane (13/37), or both (2/37). METHODS: Retrospective analysis of clinical records. RESULTS: There was no statistically significant difference between the survival times of 13 dogs treated only with mitotane when compared with 22 dogs treated only with trilostane. The median survival time for animals treated with trilostane was 353 days (95% confidence interval [CI] 95-528 days), whereas it was 102 days (95% CI 43-277 days) for mitotane. Metastatic disease was detected in 8 of 37 dogs. There was a significantly lower probability of survival for dogs with metastatic disease when compared with those without metastatic disease (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: The choice of medical treatment for ADH may not have a major effect on survival times. However, the presence of metastatic disease considerably decreases survival time regardless of the choice of medical treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21352377/